Shushan Hovsepyan, Editor-in-Chief of OncoDaily Medical Journal, shared a post on LinkedIn:
“The ESMO Sarcoma and Rare Tumor Annual Congress is approaching!
Some of the biggest discussions in sarcoma and rare tumors are about to happen.
Here are my top 7 sessions to attend:
- Combination systemic treatments with immunotherapy.
Javier Martin-Broto (Madrid, Spain) – Are new combinations the game-changer we need?
- T Cell Therapy: Next Questions.
Sandra D’Angelo (New York, US) – What’s next in making cell therapy effective for sarcomas?
- Agnostic drug development: The new frontier in oncology?
Sandra Strauss (London, UK) – Could tumor-agnostic therapies reshape treatment strategies?
- Global trends in sarcoma clinical trials: Disparities & efficiencies
Amalya Sargsyan (Yerevan, Armenia) – Why do trial access gaps still exist, and what can we do?
- New systemic treatments & trial challenges in angiosarcoma.
Bernd Kasper (Mannheim, Germany) – Why are clinical trials so difficult, and how do we fix this?
- Biology of leiomyosarcoma (LMS): What we now know.
Maria Cleofé Romagosa (Barcelona, Spain) – Are we any closer to real progress?
- Long-term nirogacestat in desmoid tumors: Updated Phase III DeFi trial data.
Bernd Kasper (Mannheim, Germany) – A new standard of care?
Did I miss any key topics? Let me know if you have additions!”
